Purpose. The effect of study-level factors on the proportion of time spent with International Normalized Ratio (INR) values inside the therapeutic range in patients treated with warfarin in the United States was evaluated. Methods. Studies evaluated in a previous meta-analysis were screened for potential inclusion, in addition to a systematic literature search of databases from January 2005 through February 2008. Studies were included if they (1) contained at least one warfarin dosing group that enrolled >25 patients for whom INR control was monitored for at least three weeks, (2) included only patients treated in the United States, (3) used a patient-time approach to report outcomes, and (4) reported proportion of time spent in the therapeutic INR range. Analyses included determining how studylevel factors, such as study setting, year of study publication, INR interpolation method, study design, and presence of selfmanagement, affected outcomes. Results. Twenty-four studies, including a total of 43 unique warfarin groups, were included in the analysis. Overall, patients spent 57% of their time in the therapeutic range (95% confidence interval [CI], 55-59%). Compared with anticoagulation clinics, community management resulted in less time (-13%; 95% CI, -18% to -7.9%) and prospective studies resulted in more time (7.3%; 95% CI, 1.5-13.1%) spent in the therapeutic range than retrospective studies. When studies from both the United States and Canada were included, similar results to those in the base-case analysis were seen; however, study year and interpolation method were also found to be significant modifiers of INR control. Conclusion. Patients included in the meta-analysis maintained INR values within the therapeutic range 57% of the time, although the use of anticoagulation clinic services appeared to be superior to standard community care in this regard. However, patients treated in anticoagulation clinics had INR values within the therapeutic range less than two thirds of the time.
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W
arfarin is the most commonly prescribed oral vitamin K antagonist (VKA) in the United States, with about 2.5 million patients receiving it in 2006. 1 It has been found to be effective for the treatment of numerous conditions ranging from thromboembolic disorders to decreasing the risk of thromboembolic events associated with atrial fibrillation. 2 However, warfarin is challenging to use given its narrow therapeutic range, high interpatient variability in response, numerous drug and food interactions, requirement for continual laboratory monitoring, and risks related to nonadherence. 2 For patients receiving warfarin, the proportion of time that their International Normalized Ratio (INR) values are outside of the therapeutic range is strongly associated with adverse outcomes. [3] [4] [5] Hylek et al. 6, 7 demonstrated in case-controlled studies that the INR was the dominant risk Although it has been hypothesized that study-level factors, such as year of study publication, study design, INR interpolation method, use of patient self-management, and warfarin dosing setting (e.g., randomized trial, anticoagulation clinic, community physician office), may explain at least some of the variance seen in INR control between randomized trials and cohort studies (and even between cohort studies), there is a paucity of studies formally testing this hypothesis.
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A meta-analysis by van A meta-analysis was conducted to evaluate the effect of study-level factors, such as study setting, year of study publication, interpolation method, study design, and the use of self-management, on the proportion of time spent within the therapeutic INR range in patients being treated with warfarin in the United States.
Methods
To ensure methodological consistency and aid in the comparison of our results to those of the previous meta-analysis conducted by van Walraven et al., 11 we used the same study selection and statistical analysis methodologies, except for the exclusion of non-U.S. studies and studies in which patients received anticoagulants other than warfarin. The methods employed conformed to the MOOSE (Meta-analysis of Observational Studies in Epidemiology) and QUOROM (Quality of Reporting of Meta-analysis) guidelines for reporting meta-analyses. 13, 14 Study selection. All studies included in the meta-analysis conducted by van Walraven et al. 11 that included reports between 1987 and 2005 were evaluated for inclusion in this analysis. Subsequent systematic literature searches were conducted in MEDLINE, EMBASE, CINAHL, Web of Science, and the Cochrane Library for dates from January 1, 2005, through the end of February 2008 to identify additional studies (either randomized or observational in design) that evaluated warfarin as an anticoagulant. The searches included the following medical subject headings and text keywords: "warfarin," "vitamin k antagonist," "VKA," "anticoagulant" and "international normalized ratio," "INR," "prothrom-bin time," "PT," and "PTR." The resulting citations were then limited to human subjects, primary studies, and English-language publications. Furthermore, a manual search of references from reports of the primary studies and review articles found was performed to identify additional relevant trials.
All potentially relevant articles were reviewed independently by two investigators. To be included in this meta-analysis, studies had to have (1) contained at least one warfarin dosing group that enrolled ≥25 patients for whom INR values were monitored for at least three weeks, (2) used a patient-time approach that required the obtainment of serial INRs for each study patient (studies were excluded if they measured serial INRs after the administration of vitamin K) and an interpolation (any interpolation method was accepted but linear was used preferentially when available) of the values between actual measures so that anticoagulation status could be estimated for each day of observation, (3) included only patients treated in the United States, and (4) reported data on the proportion of time patients receiving warfarin had INR values in traditional therapeutic INR ranges (e.g., a lower limit INR between 1.8 and 2.0 and an upper limit INR between 3.0 and 3.5). Finally, if studies reported INR control rates for the same patient group at different time periods, only the time period of the longest duration was included.
Data abstraction. All data were independently abstracted through the use of a standardized data abstraction tool by two investigators, and discrepancies were resolved by a third investigator. The following information was sought from each study: author identification, year of publication, geographic location of the study, type of study design (prospective or retrospective), INR interpolation method, type of anticoagulant used, whether of not patients were self-managed, and the study group setting. There were three categories of interpolation methods: (1) "linear interpolation" meant that INR values were assumed to change linearly between successive measures, (2) "halving interpolation" meant that the first half of the time between successive INRs was assigned the previous INR value and the second half of the time was assigned the subsequent INR value, and (3) "other interpolation" meant that a rational method that was not linear or halving was used. The study setting could be designated as being a randomized trial, anticoagulation clinic, or community practice. The designation of a randomized trial took precedent over other study settings so that all studies in our analysis designated as anticoagulation clinic or community practice were observational trials. The setting was considered a randomized trial if random allocation to assign patients to receive warfarin or another nonwarfarin therapy was employed, it was considered an anticoagulation clinic if the study was not a randomized trial and took place in an anticoagulation clinic or if the stated role of the study clinicians in patient care was limited to managing anticoagulation, and it was considered a community practice if the study could not be classified as occurring in either an anticoagulation clinic or randomized trial setting. The year in which the study was published was categorized by selecting the midpoint of all studies included.
Statistical analysis. The proportion of time spent within the therapeutic INR range for each study group was expressed as an incidence density using a person-time approach. Incidence densities were calculated as the proportion of time that the group spent within the INR range multiplied by the observation time (e.g., numerator) divided by the total observation time for each study group (or the total study observation time multiplied by the proportion of patients in each study group if the observation time for the individual study group was not reported in a given study) (e.g., denominator). Ninety-five percent CIs were calculated for each incidence density using the Wilson score method without continuity correction. 15 For the purposes of this metaanalysis, the time in the therapeutic INR range for each study group and the accompanying 95% CI was used to calculate a weighted-average pooled effect and 95% CI using a random-effects model. After finding that none of the studies conducted in the United States were randomized trials, we decided to perform a post hoc analysis including studies conducted in Canada, where clinical anticoagulation practices are similar to those in the United States and inclusion of randomized controlled trials is more likely. This analysis is supported by results of the ISAM study, which demonstrated similar anticoagulation practices and control rates between the United States and Canada. 1 We theorized that inclusion of the Canadian studies would provide additional statistical power to detect differences among the study-level factors analyzed without significant detriment to the analysis's external validity.
In order to determine the influence of the study setting, year of study publication, interpolation method, study design, and presence of self-management on the proportion of time spent within a therapeutic INR range, both subgroup and meta-regression analyses were conducted. A multiple-linear, mixed-method model using both random effects and fixed effects was used for metaregression, which was weighted using the random-effects weighting. Statistical heterogeneity was addressed using the I 2 statistic. Visual inspection of funnel plots and Egger's weighted-regression statistics were used to assess for the presence of publication bias. Statistical analysis Am J Health-Syst Pharm-Vol 66 May 15, 2009 was performed using StatsDirect version 2.4.6 (StatsDirect Ltd., Cheshire, England) and SPSS, version 15.0 (SPSS Inc., Chicago, IL).
Results
Fourteen of the studies included in the study conducted by van Walraven et al. 11 met the inclusion criteria. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] As depicted in Figure 1 , the updated systematic search identified 536 studies for full-text review, of which 526 were excluded. The most common reasons for exclusion were that the studies were not conducted within the United States and were not primary studies. Thus, an additional 10 studies 30-39 met the inclusion criteria, resulting in a total of 24 studies, including a total of 43 separate (Figure 2 ). Significant statistical heterogeneity was detected, although the presence with patients in an anticoagulation clinic spending 64% of their treatment time in the therapeutic range versus 51% with patients in community practice. As no randomized controlled trials were included in the analysis, this subgroup could not be evaluated. In addition, older studies had a lower percentage of time that INR values were in range than newer studies (51% versus 57%, respectively). Interpolation method, study design, and self-management appeared to have less of an effect on percentage of time in range than the other factors. Upon metaregression, similar results to those of the subgroup analyses were seen. We found that, after concurrently controlling for the various study level factors, both study setting and study design were significantly associated with the time spent within the therapeutic INR range (p < 0.001 and p = 0.014, respectively) ( Table 2) . Compared with anticoagulation clinics, warfarin treatment in community practice resulted in -13.0% (95% CI, -18.1% to -7.9%) time in the therapeutic INR range. In addition, prospective studies resulted in 7.3% (95% CI, 1.5-13.1%) more time spent in the therapeutic range than retrospective studies. Other factors, including interpolation method, study year, and self-management, were not found to have a statistically significant effect on time in the therapeutic range.
Upon post hoc analysis, including studies from both the United States and Canada (totaling 34 studies with 53 groups, including 6 randomized controlled trials), similar results to those in the base-case analyses were seen (Table 3) . Patients spent a total of 59% (95% CI, 57-61%) of time within the therapeutic INR range. As with the U.S.-only population, metaregression demonstrated that study setting and study design were significant predictors of anticoagulation control. In addition, the U.S. and Canada group analyses showed that study year and interpo-Am J Health-Syst Pharm-Vol 66 May 15, 2009 lation method were also statistically significant predictors of time within the therapeutic INR (p ≤ 0.02). Results for anticoagulation clinics and randomized controlled trials did not differ significantly; however, community practice had a significantly lower adjusted percentage of time in the therapeutic range (-11.3%; 95% CI, -16.2 to -6.3) than anticoagulation clinics. Similarly, prospective studies resulted in more time in the therapeutic range (9.8%; 95% CI, 4.5-15.15%) than retrospective studies. In addition, older studies resulted in less time in the therapeutic range (-8.0%, 95% CI, -14.1% to -2.0%) than newer studies, and studies that used a linear interpolation method resulted in more time in the therapeutic range (7.2%; 95% Results from a multiple-linear, mixed-method model controlling for study-level factors of study setting, study year, interpolation method, study design, and self-management.
c One study 18 could not be classified by study setting and was excluded from the study setting subgroup and metaregression analyses. CI, 1.2-13.2%) than those that used other methods. Self-management was not found to have a significant effect on the proportion of time spent within the therapeutic range.
Discussion
In our meta-analysis of studies evaluating anticoagulation control within the United States, we found that patients spent a relatively low proportion of time with INR values in the therapeutic range while receiving warfarin (57%; 95% CI, 55-59%). In addition, metaregression showed that study setting and study design were the study-level factors that had the most influence on anticoagulation control. Studies set in the community fared worse than those set in anticoagulation clinics, and prospective studies fared better than retrospective studies. It is plausible that researchers and clinicians involved with prospective studies were more cognizant of warfarin dosing and were more diligent in maintaining appropriate INR values. Interpolation method and study year were not found to significantly impact anticoagulation control. There was an insufficient number of studies to evaluate the impact of randomized controlled trials and self-management studies on anticoagulation control with warfarin. The dissemination of this type of data could lead to a stronger emphasis on tight anticoagulation control. Post hoc analyses with the addition of data from Canadian trials also supported the base-case results and showed statistical significance for additional study-level factors, likely because of increased statistical power of more included studies.
Our meta-analysis differs from meta-analyses conducted by van Walraven et al. 11 and Dolan et al. 12 in notable ways. By including only studies evaluating anticoagulation control in the United States and limiting the evaluation exclusively to warfarin, the information is more readily applicable to the U.S. population (increased external validity). We also included U.S. trials published after the previous meta-analyses were conducted, increasing the likelihood of finding differences between groups in a solely U.S. population. Dolan et al. 12 argued that their approach to trial categorization was more accurate than that of van Walraven et al. 11 since study design was merely a proxy of frequency and intensity of monitoring rather than the actual report, which may have been a more accurate assessment. Dolan et al. 12 demonstrated that more frequent monitoring and more organized care led to greater INR control, which confirmed the results of van Walraven et al. 11 and the results of the current analysis. The continued low achievement of anticoagulation control seen in our study is of concern. Patients receiving oral anticoagulants have INR values that are outside of the therapeutic range for a significant portion of time. However, as we observed in the current study, even within anticoagulation clinics, patients still spend over one third of their time with INR values that are outside of the therapeutic range. 39, [50] [51] [52] In the setting of anticoagulation clinics, newer warfarin dosing strategies, including computer-aided dosing, 16 specialty-pharmacy clinics, 26 and genotype-guided dosing, 33 have been investigated with little improvement observed in overall INR control.
There were limitations to this study. As with all meta-analyses, the Results from a multiple-linear, mixed-method model controlling for study-level factors of study setting, study year, interpolation method, study design, and self-management. One study 18 could not be classified by study setting and was excluded from the study setting subgroup and metaregression analyses. presence of publication bias is a potential concern. However, given the systematic nature of our literature search, this risk was minimized. Also, given the number of studies identified in our search, it is unlikely that additional studies would alter our conclusions. Another limitation of our meta-analysis stems from the fact that very few studies evaluating warfarin self-management were identified and, therefore, we could not adequately assess its impact on anticoagulation control. For similar reasons, the impact of randomized controlled trials on INR control could not be evaluated in the basecase analysis. Another limitation is that several factors that may influence the time within the therapeutic range were inconsistently reported among studies included in this meta-analysis. These factors include patient age, dietary intake, indication for anticoagulation, initial dose of warfarin, frequency of monitoring, duration of therapy before the study, and degree to which the INR was out of range. Because of the inconsistent reporting, these factors were not included in our analysis. Furthermore, it has been recommended that for every variable considered in a multiple-linear, mixedmethod model, there should be approximately 10 included studies in the analysis. 53 Therefore, with the number of studies included in our analysis, there was a limited number of variables that we could include, so we chose the ones that had previously been studied to have the most impact on the results. 11 However, since no significant differences were seen between randomized controlled trials and anticoagulation clinics in our sensitivity analysis of U.S. and Canadian trials or the previous study conducted by van Walraven et al., 11 we have added confidence in our finding that anticoagulation clinics and randomized trials provide similar anticoagulation control that is superior to community practice. While anticoagulation clinics provide superior INR control compared with that achieved in standard community practice, the average patient still only spends two thirds of his or her time with INR values within the therapeutic range. Therefore, patients still have a greater risk of adverse outcomes than if patients achieved a more predictable and stable level of anticoagulation. Since guidelines do not suggest an acceptable minimum time within the therapeutic range, it may be inferred that the best outcomes would result from 100% of time spent in range. Therefore, any improvements in a patient's time with INR values within the therapeutic range may be considered clinically relevant, and clinicians should still strive to improve current practice to increase the time in range.
Conclusion
Patients included in the metaanalysis maintained INR values within the therapeutic range 57% of the time, although the use of anticoagulation clinic services appeared to be superior to standard community care in this regard. However, patients treated in anticoagulation clinics had INR values within the therapeutic range less than two thirds of the time.
